← All trials
NCT04930627
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2021
- Primary completion
- Jun 30, 2024
- Completion date
- Mar 31, 2025
- First posted
- Jun 18, 2021
- Last posted
- Jun 23, 2021
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Children's Memorial Health Institute, PolandLead sponsor
- Children's Memorial Health Institute, PolandReponsible party - principal investigator
- Medical University of WarsawCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.